載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.87
−US$0.0107 · -1.21%
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
前收盤價
US$0.87
−US$0.0107 · -1.21%
盤中時間採用ET。市場資料可能有所延遲。
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
日內區間
目前US$0.87
52週區間
目前US$0.87
盤中時間採用ET。市場資料可能有所延遲。
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
日內區間
目前US$0.87
52週區間
目前US$0.87
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.4萬 USD | 2603.3萬 USD | — | — | — |
| 毛利 | 6.4萬 USD | 2603.3萬 USD | — | — | — |
| 研究與開發 | 3779.8萬 USD | 2925.6萬 USD | 5300.2萬 USD | 9663萬 USD | 8049.6萬 USD |
| 銷售、一般及管理費用 | 2034萬 USD | 1922.9萬 USD | 1605.4萬 USD | 2080.6萬 USD | 1901.4萬 USD |
| 營業費用 | 5813.8萬 USD | 4848.5萬 USD | 6905.6萬 USD | 1.19億 USD | 9810.7萬 USD |
| 利息收入 | 226.8萬 USD | 445.3萬 USD | 5199 USD | 156.5萬 USD | 9.77萬 USD |
| 利息支出 | — | — | — | 2.1萬 USD | 6909.14 USD |
| 折舊和攤銷 | 70.4萬 USD | 66萬 USD | 72萬 USD | 103.1萬 USD | 63.4萬 USD |
| 營業利益 | −5807.4萬 USD | −2245.2萬 USD | −6905.6萬 USD | −1.19億 USD | −9810.7萬 USD |
| 淨利 | −5548萬 USD | −1562.8萬 USD | −6210.6萬 USD | −1.18億 USD | −2.02億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.60
上漲空間 658.62%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM34.54萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO19.35萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO10萬0.00%139.17億 USD0.24%US$356.78+0.94%
iShares Micro-Cap ETFIWC4.18萬0.00%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG2.17萬0.00%17億 USD0.06%US$260.49+0.91%
Vanguard Russell 2000 Value ETFVTWV1.45萬0.00%14億 USD0.06%US$185.81-0.13%
Global X - Russell 2000 ETFRSSL6265.74—14.19億 USD0.08%US$109.09+0.21%
ProShares Russell 2000 High Income ETFITWO760.380.00%1.85億 USD0.55%US$43.06+0.96%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGVanguard Russell 2000 Value ETFVTWVGlobal X - Russell 2000 ETFRSSLProShares Russell 2000 High Income ETFITWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
